Workers Compensation
The medications most often prescribed after an injury share a small set of side effects, and those side effects look exactly like the conditions injured people are expected to develop. This reference lists the most common misreads, drug by drug, so a claims manager can recognise the pattern before funding a new diagnosis.
Why do injury medications produce so many look-alike symptoms?
Opioids, gabapentinoids, benzodiazepines, sedating antidepressants, muscle relaxants and anti-inflammatories are the core of most personal injury regimens. Almost all of them act on the central nervous system, and almost all of them produce sedation, dizziness, cognitive slowing and mood change at therapeutic doses. Add the gastrointestinal, cardiovascular and metabolic effects of the same drugs and the overlap with "the injury got worse" or "the claimant developed a secondary condition" is nearly complete. The framework for testing any individual symptom is in the pillar guide on side effects versus new diagnoses; this article is the look-up table.
Which symptoms are most often misread, and which drugs cause them?
| Symptom on the claim | Usually diagnosed as | Medications that commonly cause it | Discriminating question |
|---|---|---|---|
| Fatigue, daytime somnolence, "can't function" | Depression, chronic fatigue, deconditioning, sleep disorder | Opioids, pregabalin and gabapentin, benzodiazepines, mirtazapine, amitriptyline, sedating antihistamines, baclofen, cyclobenzaprine | Did it begin or worsen after a dose increase or a new sedating agent? Total sedative load, not any one drug, is the usual cause |
| Dizziness, unsteadiness, falls | Vestibular disorder, postural hypotension of unknown cause, "post-concussion" | Pregabalin, gabapentin, opioids, benzodiazepines, tricyclics, antihypertensives, prazosin, tamsulosin | Is a vestibular sedative such as prochlorperazine about to be added to treat a drug-induced dizziness? |
| Cognitive slowing, poor memory, word-finding difficulty | Mild cognitive impairment, post-traumatic brain injury, depression with cognitive features | Gabapentinoids, opioids, benzodiazepines, anticholinergics (amitriptyline, oxybutynin, some antihistamines), topiramate | Has anyone calculated the anticholinergic and sedative burden before ordering neuropsychology? |
| Constipation, bloating, abdominal pain, nausea | Irritable bowel, gastrointestinal disease, food intolerance | Opioids (all), tricyclics, iron, calcium channel blockers, anticholinergics | Opioid-induced constipation affects the majority of long-term opioid users and does not resolve with tolerance. Has a laxative cascade begun? |
| Reflux, dyspepsia | GORD, peptic ulcer disease | NSAIDs, opioids (delayed gastric emptying), bisphosphonates, some antidepressants | Is a proton pump inhibitor being added while the NSAID continues? |
| Peripheral oedema, swollen ankles | Cardiac failure, venous insufficiency, DVT query | Pregabalin, gabapentin, amlodipine and other calcium channel blockers, NSAIDs, pioglitazone | Has a diuretic been added to treat a gabapentinoid or calcium channel blocker effect? This is the best-documented cascade in the literature |
| Low mood, tearfulness, anhedonia | Secondary depressive disorder, adjustment disorder | Opioids, benzodiazepines, gabapentinoids, corticosteroids, beta-blockers, isotretinoin, varenicline | Did mood decline track a sedative or opioid escalation? See the companion article on medication-induced psychological symptoms |
| Anxiety, agitation, irritability, insomnia | Anxiety disorder, PTSD features, sleep disorder | SSRIs and SNRIs on initiation, corticosteroids, stimulants, pseudoephedrine, benzodiazepine or opioid interdose withdrawal, tramadol | Are the symptoms worst before the next dose is due? Interdose withdrawal is routinely misread as the underlying anxiety worsening |
| New or worsening widespread pain | Injury progression, fibromyalgia, central sensitisation | Opioid-induced hyperalgesia at higher doses, statin myalgia, aromatase inhibitors, fluoroquinolones | Did pain spread beyond the injury site as the opioid dose rose? Opioid-induced hyperalgesia improves on dose reduction, progression does not |
| Weight gain | Deconditioning, metabolic syndrome | Mirtazapine, amitriptyline, pregabalin, gabapentin, olanzapine and quetiapine, corticosteroids, some SSRIs | Is the weight gain being treated with lifestyle programs while the drug that caused it continues? |
| Sexual dysfunction, low libido | Relationship breakdown, depression, hormonal disorder | SSRIs and SNRIs, opioids (via hypogonadism), beta-blockers, finasteride | Long-term opioids suppress testosterone. Has that been checked before an endocrine work-up? |
| Dry mouth, urinary retention, blurred vision | Sjogren's, prostate disease, ophthalmic referral | Amitriptyline, nortriptyline, oxybutynin, cyclobenzaprine, antihistamines, some antipsychotics | Anticholinergic burden. Is an alpha-blocker about to be added for a drug-induced urinary symptom? |
| Tremor, restlessness, stiffness | Parkinsonism, essential tremor, anxiety | Metoclopramide, prochlorperazine, antipsychotics, SSRIs, sodium valproate | Is an anti-parkinsonian agent being considered for a drug-induced movement disorder? |
Which of these matter most on a personal injury claim?
Four rows in that table carry most of the cost. Sedation and cognitive slowing, because they are the symptoms most likely to be certified as incapacity for work and most likely to trigger neuropsychological assessment. Low mood and anxiety, because they are the gateway to a secondary psychological injury claim, which in NSW now averages $288,542 against 12 per cent of claims accounting for 38 per cent of cost. Dizziness and falls, because a fall on a claim is a new injury with its own treatment stream, and because the reflex response, a vestibular sedative, adds a further sedating drug. And new pain, because opioid-induced hyperalgesia read as progression produces the single most expensive wrong turn in injury pharmacology: more opioid, more imaging, more specialist input, and a claimant in more pain than before.
What is the pattern behind the pattern?
Two mechanisms explain most of the table. The first is cumulative sedative and anticholinergic load. An injured worker on oxycodone, pregabalin, amitriptyline and an antihistamine for sleep is on four sedating, three anticholinergic agents. Each is a modest dose. Together they produce the fatigue, fog, constipation, dry mouth and unsteadiness that get investigated as four separate problems. The second is tolerance and interdose withdrawal. Opioids and benzodiazepines taken on a schedule produce a trough before each dose in which pain, anxiety, sweating and irritability spike. Patients and prescribers read the trough as the underlying condition breaking through, and the response is a higher or more frequent dose, which deepens the next trough. Both mechanisms are described in detail in the article on prescribing cascades in personal injury claims.
What should a claims manager do when a row in this table matches?
Do not fund the new diagnosis first. Ask for the medication chronology and line the symptom against it. If a drug in the third column started or escalated before the symptom in the first column, write to the treating practitioner asking whether the medication has been considered as the cause and whether a supervised reduction is appropriate before further investigation. Where the practitioner disagrees, or the regimen has more than four or five agents, refer for an independent clinical pharmacy review. A pharmacist will assess causality for each symptom, quantify sedative and anticholinergic load, and recommend a reduction sequence. Where psychological symptoms are the issue, the specific liability considerations are set out in the article on medication-induced psychological symptoms and secondary injury claims.
Key Takeaways
- The core injury medications (opioids, gabapentinoids, benzodiazepines, sedating antidepressants) all produce fatigue, dizziness, cognitive slowing and mood change, which are also the expected symptoms of a bad injury.
- The most expensive misreads are sedation certified as incapacity, drug-induced low mood treated as secondary psychological injury, drug-induced dizziness leading to falls, and opioid-induced hyperalgesia treated as progression.
- Cumulative sedative and anticholinergic load, not any single drug, is the usual cause of fatigue, fog, constipation and unsteadiness.
- Interdose withdrawal from opioids and benzodiazepines is routinely misread as the underlying pain or anxiety worsening, and answered with a higher dose.
- A symptom that follows a medication change and matches that drug's product information is the leading diagnosis until reduction has been tried.
- Ask for the medication chronology before funding the new diagnosis, and refer for pharmacist review when the regimen exceeds four or five agents.
Frequently Asked Questions
Does opioid-induced constipation go away with time?
No. Unlike sedation and nausea, tolerance does not develop to opioid-induced constipation. It persists for as long as the opioid continues and is frequently investigated and treated as a gastrointestinal condition in its own right rather than managed by reducing the opioid.
What is opioid-induced hyperalgesia and how is it different from worsening injury?
Opioid-induced hyperalgesia is a paradoxical increase in pain sensitivity caused by prolonged or high-dose opioid exposure. Pain becomes more diffuse and spreads beyond the injury site, and it improves when the opioid dose is reduced. Injury progression stays localised and does not improve with opioid reduction. On a claim the distinction determines whether the right response is more opioid or less.
Can pregabalin cause cognitive impairment?
Yes. Dizziness, somnolence and impaired concentration are among the most common adverse effects of pregabalin and gabapentin, and they are dose-related. Injured workers on gabapentinoids who are referred for neuropsychological assessment of cognitive complaints should have the gabapentinoid considered and, where appropriate, reduced first.
How many medications before a pharmacist review is warranted?
Adverse effect risk rises sharply above four or five regular medications, and any regimen with more than one sedating or anticholinergic agent warrants review regardless of count. A new symptom or diagnosis appearing after a medication change is an independent trigger at any regimen size.
Primary sources: Kalisch et al, The prescribing cascade, Australian Prescriber 2011; Australian Medicines Handbook and TGA-approved product information for the medications listed; Rochon and Gurwitz, Lancet 2017; Tefera et al, British Journal of Clinical Pharmacology 2026; Di Donato et al, CNS Drugs 2025; NSW workers compensation reform data, 2026.
